Oct 7, 2022 2:29 AM
BACK TO TOP
KSE100
42,160.57
549.15
(1.32%)
ALLSHR
28,642.96
263.90
(0.93%)
KSE30
15,894.70
290.34
(1.86%)
KMI30
70,169.84
1332.66
(1.94%)
BKTi
9,941.57
101.07
(1.03%)
OGTi
10,210.84
187.57
(1.87%)
KMIALLSHR
21,132.99
219.25
(1.05%)
PSXDIV20
13,718.47
231.05
(1.71%)
UPP9
10,772.28
224.88
(2.13%)
NITPGI
8,933.96
175.90
(2.01%)
NBPPGI
10,975.52
189.23
(1.75%)
MZNPI
9,009.63
208.51
(2.37%)
JSMFI
9,987.56
218.28
(2.23%)
ACI
8,543.41
80.95
(0.96%)
HBLTTI
10,178.99
05-10-2022
4.23
(0.04%)
GlaxoSmithKline Pakistan Limited
PHARMACEUTICALS
Rs.112.50
-0.01
(-0.01%)
1D
1M
6M
YTD
1Y
3Y
5Y
As of Thu, Oct 6, 2022 3:38 PM
REG
FUT
ODL
Open
112.94
High
112.94
Low
111.51
Volume
4,000
CIRCUIT BREAKER
104.07 — 120.95
DAY RANGE
111.51 — 112.94
52-WEEK RANGE
110.00 — 152.90
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0
LDCP
112.51
VAR
11.00
HAIRCUT
15.00
P/E Ratio (TTM) **
8.37
1-Year Change *
-24.50%
YTD Change *
-17.59%

No record found

Open
111.02
High
111.99
Low
111.02
Close
111.99
Change
-0.46%
LDCP
112.51
Volume
7
Total Trades
3
CIRCUIT BREAKER
101.26 — 123.76
DAY RANGE
111.02 — 111.99
Ask Price
112.00
Ask Volume
11
Bid Price
111.23
Bid Volume
1
Market data powered by capitalstake.com. Provided by PSX. ** Based on unconsolidated financials
  * Returns not adjusted for payouts

Company Profile

BUSINESS DESCRIPTION

GlaxoSmithKline Pakistan Limited is incorporated in Pakistan as a limited liability company. It is engaged in manufacturing and marketing of research based ethical specialties and pharmaceutical products. The Company is a subsidiary of S.R. One International B.V., incorporated in Netherlands, whereas its ultimate parent company is GlaxoSmithKline plc, UK (GSK plc).

KEY PEOPLE
Ms. Erum Shakir RahimCEO
Chairman
Ms. Mehar-e-daraksha AmeerCompany Secretary
ADDRESS

35 - Dockyard Road, West Wharf, Karachi

WEBSITE

www.pk.gsk.com

REGISTRAR

CDC Share Registrar Services Limited CDC House, 99 - B, Block - B S.M.C.H.S., Main Shahra-e-Faisal Karachi

AUDITOR

Yousuf Adil, Chartered Accountants

Fiscal Year End

December

Equity Profile

Market Cap (000's)
35,827,568.78
Shares
318,467,278
Free Float
52,111,650
Free Float
16.36%

Announcements

Financial Results
Board Meetings
Others
DateTitleDocument
Aug 29, 2022Transmission of Quarterly Report for the Period Ended June 30, 2022 View   PDF
Aug 23, 2022Financial Results for the Quarter Ended June 30, 2022 View   PDF
May 6, 2022Transmission of Quarterly Report for the Period Ended March 31, 2022 View   PDF
Apr 26, 2022Financial Results for the Quarter Ended March 31, 2022 View   PDF
Apr 4, 2022Transmission of Annual Report for the Year Ended 2021-12-31 View   PDF
Feb 25, 2022Financial Results for the Year Ended December 31 2021 View   PDF
Oct 29, 2021Transmission of Quarterly Report for the Period Ended September 30, 2021 View   PDF
Oct 25, 2021Financial Results for the Quarter Ended September 30, 2021 View   PDF
Aug 27, 2021Transmission of Quarterly Report for the Period Ended 2021-06-30 View   PDF
Aug 23, 2021Financial Results for the Quarter ended June 30, 2021 View   PDF
DateTitleDocument
Aug 16, 2022Board of Directors Meeting - August 23, 2022 View   PDF
Apr 25, 2022Board Meeting In Progress View   PDF
Apr 25, 2022Certified True Copy of Resolution - Annual General Meeting View   PDF
Apr 18, 2022Board Meeting View   PDF
Apr 4, 2022Notice of Annual General Meeting View   PDF
Feb 18, 2022BOARD OF DIRECTORS MEETING View   PDF
Oct 18, 2021Board of Directors Meeting View   PDF
Aug 20, 2021Board Meeting Reschedule View   PDF
Aug 16, 2021Board of Directors Meeting View   PDF
Apr 27, 2021MEETING IN PROGRESS View   PDF
DateTitleDocument
Sep 28, 2022Appointment of Non-Executive Director View   PDF
Sep 28, 2022Appointment of Non-Executive Director View   PDF
Sep 16, 2022GLAXO | GlaxoSmithKline Pakistan Limited
REVISED
PDF
Sep 16, 2022GLAXO | GlaxoSmithKline Pakistan Limited - Panadol Information
REVOKED
PDF
Aug 12, 2022Appointment of Ms. Lai Kuen Goh - Chairperson and Non-Executive Director View   PDF
Aug 10, 2022Resignation of Mr. Dmytro Oliinyk from the Board of GlaxoSmithKline Pakistan Limited View   PDF
Jun 30, 2022Material Information - Resignation of Mark Dawson as Director w.e.f. 30 June 2022 View   PDF
Jun 8, 2022Material Information View   PDF
May 10, 2022Credit of Final Cash Dividend 2021 View   PDF
May 6, 2022PRIOR PUBLICAITON NOTICE OF DIRECT CREDIT OF FINAL CASH DIVIDEND View   PDF
Mar 30, 2022Prior Publication of AGM Notice for the year 2021 View   PDF
Dec 6, 2021Corporate Briefing Session View   PDF

Financials

All numbers in thousands (000's) except EPS

Annual
Quarterly
2021202020192018
Sales36,660,77235,090,11236,581,74934,006,840
Profit after Taxation5,354,4093,375,2403,041,1233,257,951
EPS16.8110.609.5510.23
Q2 2022Q1 2022Q3 2021Q2 2021
Sales9,542,3778,625,9649,825,2269,058,094
Profit after Taxation(293,829)925,0411,195,203977,497
EPS(0.92)2.903.753.07
Data powered by Capital Stake. To provide comparable data, information might have been standardized. The data presented may therefore differ from issuer's annual report and 'as reported' data should be obtained directly from the source issuer. See the Capital Stake Terms of Use.

Ratios

2021202020192018
Gross Profit Margin (%)26.5621.4721.0824.74
Net Profit Margin (%)14.619.628.319.58
EPS Growth (%)58.5810.99(6.65)9.29
PEG0.141.65(2.53)1.19

Payouts

DateFinancial ResultsDetailsBook Closure
February 28, 2022 11:32 AM31/12/2021(YR) 70%(F) (D) 19/04/2022 - 25/04/2022
March 10, 2021 3:45 PM31/12/2020(YR) 65%(F) (D) 21/04/2021 - 27/04/2021
March 11, 2020 5:58 PM31/12/2019(YR) 60%(F) (D) 15/05/2020 - 21/05/2020
March 4, 2019 4:53 PM31/12/2018(YR) 70%(F) (D) 18/04/2019 - 24/04/2019
February 27, 2018 3:59 PM31/12/2017(YR) 40% (D) 18/04/2018 - 24/04/2018
October 26, 2017 5:47 PM30/09/2017(IIIQ) 30% (D) 10/11/2017 - 17/11/2017
March 8, 2017 4:03 PM31/12/2016(YR) 60% (D) 18/04/2017 - 24/04/2017
March 30, 2016 3:13 PM31/12/2015(YR) 40% (D) 20/04/2016 - 27/04/2016
February 25, 2015 3:51 PM31/12/2014(YR) 50% (D) 16/04/2015 - 23/04/2015
February 7, 2014 3:24 PM31/12/2013(YR) 35% (D) - 10% (B) 21/04/2014 - 28/04/2014

Financial Reports